Table 3.
Characteristics of EC patients with and without prior/concurrent ovarian cancer.
| Characteristics | EC patients - no Ovarian Cancer (N = 1369) | aEC patients with Ovarian Cancer (N = 30) | cP |
|---|---|---|---|
| bN (%) | bN (%) | ||
| Endometriosis | 166 (12.1) | 13 (43.3) | 2.1 × 10−4 |
| Leiomyomas | 799 (58.4) | 18 (60.0) | 0.6 |
| Adenomyosis | 561 (41.0) | 11 (36.7) | 0.7 |
| Mean age at EC diagnosis (range) | 61.5 (26.4–80.0) | 54.4 (33.3–75.9) | 5.0 × 10−5 |
| Body Mass Index | |||
| <25 | 340 (25.0) | 7 (23.3) | |
| 25–29.9 | 346 (25.4) | 9 (30.0) | |
| ≥30 | 676 (49.6) | 14 (46.7) | 0.8 |
| Oral Contraceptive use | |||
| never | 448 (32.7) | 8 (26.7) | |
| ever | 920 (67.3) | 22 (73.3) | 0.9 |
| Parity | |||
| 0 | 237 (17.3) | 10 (33.3) | |
| 1 | 132 (9.6) | 8 (26.7) | |
| ≥2 | 1,000 (73.0) | 12 (40.0) | 0.03 |
| Age at Menarche | |||
| ≤11 | 305 (22.5) | 9 (30.0) | |
| 12–13 | 651 (48.0) | 15 (50.0) | |
| ≥14 | 400 (29.5) | 6 (20.0) | 0.3 |
| Smoking | |||
| never | 890 (65.1) | 18 (60.0) | |
| ever | 478 (34.9) | 12 (40.0) | 0.8 |
| dFamily History of any cancer | |||
| no | 492 (35.9) | 6 (20.0) | |
| yes | 877 (64.1) | 24 (80.0) | 0.07 |
| dFamily History of breast cancer | |||
| no | 961 (70.3) | 14 (46.7) | |
| yes | 406 (29.7) | 16 (53.3) | 0.003 |
| dFamily History of any Lynch cancer | |||
| no | 665 (48.6) | 13 (43.3) | |
| yes | 704 (51.4) | 17 (56.7) | 0.7 |
| eTumor Histology & Grade | |||
| Endometrioid Grade 1 | 712 (52.0) | 13 (43.3) | 0.3 |
| Endometrioid Grade 2 | 339 (24.8) | 10 (33.3) | 0.3 |
| Endometrioid Grade 3 | 119 (8.7) | 1 (3.3) | 0.3 |
| Serous (>5%) | 110 (8.0) | 1 (3.3) | 0.3 |
| Clear Cell (>10%), no serous | 34 (2.5) | 1 (3.3) | 0.8 |
| Carcinosarcoma | 41 (3.0) | 3 (10.0) | 0.03 |
| Other epithelial | 14 (1.0) | 1 (3.3) | 0.2 |
| FIGO stage | |||
| I | 1,140 (83.7) | 16 (53.3) | |
| II | 93 (6.8) | 5 (16.7) | |
| III | 107 (7.9) | 7 (23.3) | |
| IV | 22 (1.6) | 2 (6.7) | 6.6 × 10−5 |
| Lymphovascular Space Involvement | |||
| No/Unknown | 1081 (79.0) | 20 (66.7) | |
| Yes | 288 (21.0) | 10 (33.3) | 0.07 |
EC, endometrial cancer.
aOvarian cancer was concurrent with EC in 28 patients and prior to EC in 2 patients; Tumor mismatch repair (MMR) status was known for 17 individuals;12 were MMR proficient, 4 were MMR deficient due to MLH1 somatic inactivation (methylation, somatic variant), and 1 MMR deficient individual carried an MLH1 truncating variant considered pathogenic.
bNs may not sum to the total because of missing or unknown data; proportions (%) sum to 100% of observations where data available and excludes missing/unknowns. Ns for endometriosis, leiomyomas and adenomyosis are for each individual condition irrespective of coexistence of either of the other two
cP-values are P-Trend across ordered groups (BMI, Parity, age at menarche, FIGO stage) or logistic regression models for binary variables adjusted for age at EC diagnosis; P-values for tumor histology subtypes are from comparison of proportions.
dCancer reported in at least one first- degree or second-degree relative; Lynch cancers are cancer of the bile duct, bladder, brain, colon/rectum, duodenum, endometrium, gastrointestinal/GI, ovary/fallopian tube, pancreas, renal pelvis, stomach.
eEndometrioid tumor histology and grade were combined into a single variable for Endometrioid Grades 1, 2, or 3; other epithelial include mixed subtypes where serous or clear cell component does not reach % noted, or where the histology was unknown (2 individuals diagnosed by curettage).